AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
Vertex Pharmaceuticals Incorporated
Video analysis: VRTX
All videosNo video analysis for this stock yet. Request one from our team.
News: VRTX
Strong Core Business, Raised Guidance Push Vertex Pharmaceuticals Higher
Since 2008, Vertex Pharmaceuticals, Inc. (VRTX) shares have received 42 outlier institutional inflow signals and gained over 1,682%.
Vertex Pharmaceuticals Incorporated (VRTX) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript
Vertex Pharmaceuticals Incorporated (VRTX) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript
Vertex Pharmaceuticals Incorporated (VRTX) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
Vertex Pharmaceuticals Incorporated (VRTX) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
Vertex Pharmaceuticals (VRTX) Suffers a Larger Drop Than the General Market: Key Insights
In the most recent trading session, Vertex Pharmaceuticals (VRTX) closed at $528.9, indicating a -3.15% shift from the previous trading day.
Goldman Sachs Just Added Vertex Pharmaceuticals to Its Conviction List. Here's the Bull Case for the Big Biotech Stock
Vertex Pharmaceuticals' core business is rock-solid, but it is also slowly expanding into new areas. The company should see improved top-line growth over the next few years, driven by new launches.
Investors Heavily Search Vertex Pharmaceuticals Incorporated (VRTX): Here is What You Need to Know
Vertex (VRTX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Rep. David Taylor discloses 6 new Congressional stock trades
Representative David J. Taylor, a Republican from Ohio, has reported six congressional stock trades, selling off holdings in biotech and technology while purchasing shares in utility, semiconductor, and a regional bank.
3 Stocks Whose Competitive Walls Tower Over Nvidia's
Tech giant Nvidia has remained ahead of rivals thanks to its competitive advantage. These healthcare companies have proven expertise in their fields -- and they would be difficult to unseat.
